Individualized therapy of disseminated cancer using malignant melanoma as a model

Cancer and Metastasis Reviews

Volumn 25, Issue 2, 2006, Pages 253-256

  Hauschild, Axel ^a,c   Egberts, Friederike ^a   Russo, Paul ^b   Kähler, Katharina C ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Individualized therapy; Malignant melanoma

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; DACARBAZINE; ERLOTINIB; GEFITINIB; HEDI J22; HISTONE DEACETYLASE INHIBITOR; INTERFERON; LENALIDOMIDE; MONOCLONAL ANTIBODY LM 609; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OBLIMERSEN; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VASCULAR TARGETING AGENT;

ABDOMINAL DISCOMFORT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BIOLOGY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STATISTICS; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISSEMINATED CANCER; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEALTH CARE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; STANDARD; THROMBOCYTOPENIA; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; MELANOMA; NEOPLASM METASTASIS; OLIGONUCLEOTIDES, ANTISENSE; SIGNAL TRANSDUCTION; THIONUCLEOTIDES;

EID: 33745080277     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-006-8505-5     Document Type: Conference Paper

References (18)

1. Balch CM, Soong SJ, Gershenwald JE: Prognostic factors analysis of 17.600 melanoma patients: Validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001
2. Eigentler TK, Caroli UM, Radny P, Garbe C: Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759, 2003
3. Hauschild GC et al. www.ado-homepage.de, German Melanoma Guidelines, 2005
4. Cheson BD: Individualizing therapy for the hematologic malignancies: The stuff of genes and dreams. J Clin Oncol 23: 6283-6284, 2005
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005
6. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23: 5088-5093, 2005
7. Jansen B, Schlagbauer-Wadl H, Brown BD: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234, 1998
8. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H: Cehmosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728-1733, 2000
9. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002
11. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH: Cancer 104: 1045-1048, 2005
12. Mani A, Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 21: 4776-4789, 2005
13. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W: A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103: 2584-2589, 2005
14. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912-3922, 2005
15. Gasparini G, Longo R, Fanelli M, Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions
16. Hwu WJ, Lis E, Menell JH, Panageas KS. Lamb LA, Merrell J: Temozolomide plus thalidomide in patients with brain metastases from melanoma: A phase II study. Cancer 103: 2590-2597, 2005
17. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005
18. Hersey P, Sosman J, O'Day S, Richards J, Bedikian, Gonzalez R, Sharfman W, Weber R, Logan T, Kirkwood JM : A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 8avb3) integrin ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol 23( Suppl 16S): 711, 2005 (Abstract)